Quick Update for Sarepta Therapeutics (SRPT) Investors

By Chris Stiles • Tuesday, December 05 17:16 • Permanent Link

Sarepta Therapeutics marked a 2.3% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $88.14? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
Sarepta Therapeutics belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
The company's P/B ratio is 10.79
Sarepta Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -11.3 based on its trailing 12 month price to earnings (EPS) of $-7.8 per share
Its forward P/E ratio is 42.4, based on its forward earnings per share (EPS) of $2.08
SRPT has a Price to Earnings Growth (PEG) ratio of -0.13, which shows the company has a fair value when we factor growth into the price to earnings calculus.
Over the last four years, Sarepta Therapeutics has averaged free cash flows of $-397039666.7, which on average grew -5.0%
SRPT's gross profit margins have averaged -93.2 % over the last four years and during this time they had a growth rate of 17.3 % and a coefficient of variability of 47.8 %.
Sarepta Therapeutics has moved -27.0% over the last year compared to 17.0% for the S&P 500 -- a difference of -44.0%
SRPT has an average analyst rating of buy and is -37.17% away from its mean target price of $140.28 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.